

1 **Toward Precision Medicine in Aortopathies: Genetic Insights from a Brazilian Cohort** 2 **Through Targeted Next-Generation Sequencing**

3

4 Juliana R. Ferreira,¹ Julia P. Perreira,¹ Anna Paula A. Botelho,¹ Daniele N. Aprijo,² Marcelo
5 M. Melo,¹ Helena C. V. Rey,¹ Glauber M Dias²

6

7 1- Instituto Nacional de Cardiologia, Rio de Janeiro, RJ, zip code 22240-002, Brazil

8 2- Laboratório de Biologia Celular e Tecidual, Universidade Estadual do Norte Fluminense
9 Darcy Ribeiro, Campos dos Goytacazes, RJ, zip code 28013-602, Brazil.

10

11 **Corresponding author:**

12 Glauber M Dias

13 glauber@uenf.br

14

15 **ABSTRACT**

16

17 Thoracic aortic diseases (or aortopathies) result from complex interactions between genetic
18 and hemodynamic factors. Often clinically silent, these diseases can lead to lethal
19 complications like aortic dissection or rupture. This study focused on a Brazilian cohort of 79
20 individuals with thoracic aortic diseases, exploring genetic factors through targeted next-
21 generation sequencing (tNGS) of 15 priority genes. The majority of individuals had non-
22 syndromic aortopathy, with eight diagnosed with Marfan syndrome (MFS). Pathogenic or
23 likely pathogenic variants (PV/LPV) were found in five genes, including FBN1, ACTA2,
24 TGFBR2, MYLK, and SMAD3. Notably, novel variants in FBN1 were identified, contributing
25 to Marfan-like phenotypes. The diagnostic yield for isolated aortopathies was 7.1%, rising to
26 55.5% for syndromic cases. Variants of uncertain significance (VUS) were identified,
27 emphasizing the need for further research and familial investigations to refine variant
28 classifications. This study provides valuable insights into the genetic landscape of
29 aortopathies in Brazil, aiding early diagnosis and personalized management.

30

31

32 **Keywords:** Aortic Aneurysm Thoracic, Fibrilin-1, Aneurism dissecting, Genetic testing, High-
33 Throughput nucleotide sequencing

34 INTRODUCTION

35

36 Aortopathies are diseases that affect the aortic artery and can occur either as an
37 isolated characteristic or as part of a syndromic condition. Their development is linked to a
38 complex interplay of genetic and hemodynamic factors. It is a clinically silent disease with a
39 natural history of lethality, progressing to aortic dissection or rupture, where half of the
40 patients die before reaching emergency services (1,2). The Centers for Disease Control and
41 Prevention (CDC) reports that aortic aneurysms (thoracic and abdominal) are the 15th
42 leading cause of death in individuals over 55 years old and the 19th leading cause of death
43 overall (3). In Brazil, we can observe that the average annual mortality was 12,820 deaths
44 due to aortic diseases, with a total of 128,204 deaths in the last 10 years and a mortality rate
45 of 5.89 (4).

46 Thoracic aorta diseases (TAD) can be associated with inherited genetic alterations,
47 whereas those affecting the abdominal aorta are more commonly of degenerative origin and
48 related to age and/or risk factors such as hypertension, smoking, dyslipidemia, and gender
49 (5). Hereditary thoracic aortic diseases (HTAD) are characterized by progressive
50 enlargement of the ascending aorta that predisposes to acute dissections (familial thoracic
51 aortic aneurysms /dissections) (6). HTAD can be divided into syndromic and non-syndromic
52 types. Among syndromic TADs, Marfan syndrome (MFS) is the primary type, followed by
53 Loeys-Dietz syndrome (LDS) and Ehlers-Danlos syndrome (EDS), as well as other rarer
54 conditions (7). However, these syndromes contribute to only approximately 5% of all TAD
55 cases, while non-syndromic thoracic aortic diseases (NS-TAD) account for 95% of cases and
56 are further divided into sporadic and familial forms (8).

57 The genetic factors associated with TADs are inherited as monogenic mutations with
58 an autosomal dominant inheritance pattern (9). Detection of a pathogenic mutation is useful
59 for identifying an individual at risk of a potentially lethal aortic acute event (10). The known
60 genes implicated in this process encode members of the TGF β signaling pathway (TGFBR1,
61 TGFBR2, TGFB2, SMAD3), components of the aortic wall extracellular matrix's structure and
62 integrity (FBN1, COL3A1, LOX); or those affecting the function of smooth muscle cells,
63 including actin (ACTA2), myosin (MYH11), myosin light chain kinase (MYLK), and protein
64 kinase cGMP-dependent 1 (PRKG1) (11,12).

65 The priority genes for TAD can be used to target research and diagnostic panels for
66 aortopathies (13). However, for NS-TADs, the detection rate of variants in these genes is
67 approximately 20-30% (7,10), suggesting the involvement of other mechanisms (genetic or
68 non-genetic) in the pathophysiology. In Brazil, the frequency or incidence of variants in NS-
69 TADs is unknown. We selected a cohort of 79 individuals with isolated and syndromic TADs
70 from Brazil for genetic evaluation through NGS using a targeted gene panel. Here, we report
71 the findings of the genetic screening of a Brazilian cohort of aortopathies.

72

73

74 **SUBJECTS AND METHODS**

75

76 ***Study Population:***

77

78 Patients diagnosed with thoracic aortic aneurysm (TAA), aortic dissection, and aortic
79 coarctation before the age of 60, who were under the care of a quaternary cardiology center
80 in Brazil, were recruited for this study. Inclusion criteria encompassed patients with
81 suspected or confirmed clinical diagnosis of syndromic and non-syndromic aortopathies, all
82 of whom were below 60 years of age (y) at the time of diagnosis. Patients with or without a
83 family history of aortopathies, as well as those clinically suspected of having MFS, LDS and
84 EDS were considered. Exclusion criteria included other causes of aortopathies such as
85 familial dyslipidemia, syphilis, autoimmune and inflammatory diseases, and trauma. A total of
86 358 patients were evaluated, out of which 103 met the inclusion criteria. After assessing the
87 exclusion criteria, 24 patients were excluded, leaving 79 participants for the study.

88

89 ***Data Collection:***

90

91 Data collection involved retrospective and prospective evaluation of patients from the date of
92 diagnosis until December 2021. Patients were monitored for the occurrence of aortopathy-
93 related complications (acute aortic syndrome, indication for aortic surgery) and mortality.

94

95 ***Ethical Approval and Informed Consent:***

96

97 This study received approval from the National Institute of Cardiology Research Ethics
98 Committee (CAAE18868119.5.0000.5272), and all patients provided written informed
99 consent.

100

101 ***Genetic analysis***

102

103 Genetic analysis of NS-TAD patients was performed by targeted next-generation
104 sequencing (tNGS) using a panel of 15 priority genes associated with aortic diseases
105 (*ACTA2*, *COL3A1*, *FBN1*, *LOX*, *MFAP5*, *MYH11*, *MYLK*, *PRKG1*, *SMAD3*, *TGFB2*,
106 *TGFBR1*, *TGFBR2*, *EFEMP2*, *SMAD2*, *FOXE3*) (13). Sequencing was performed using
107 an Ion Torrent PGM platform (Thermo Fisher Scientific).

108

109 Patients with clinical diagnosis (or suspect) of SMF were evaluated by direct
110 sequencing of the coding regions of the *FBN1* gene. Reads were compared with the
111 RefSeq NG_008805 using the Geneious Prime Software (Biomatters Ltd).

111

112 Detailed information on DNA extraction, targeted next-generation sequencing Ion
113 Torrent PGM (Thermo Fisher Scientific), direct Sanger sequencing are provided in the
114 Supplementary Materials and Methods.

114 **Variants classification**

115

116 The variant call files (VCF) were subjected to a series of filters to exclude benign
117 polymorphisms and intronic variants. These filters selected variants located in exons, splice
118 sites, and 3'/5' UTRs with sequencing coverage $\geq 20x$ and minor allele frequency (MAF) $<$
119 0.0005 in the general population (gnomAD, <https://gnomad.broadinstitute.org/>). Check of
120 strand bias, indels in homopolymer and high frequency in internal samples were applied to
121 detect and exclude false positives (sequencing artifacts). The remaining variants were
122 classified according to the criteria set forth by the American College of Medical Genetics and
123 Genomics (ACMG) and updates, and the Clinical Genome Resource (ClinGen) (14-17).
124 Sequencing artifact suspects and clinical relevant variants were confirmed by direct
125 sequencing. Reportable variants in this work were pathogenic variants (PV), likely
126 pathogenic variants (LPV), and variants of uncertain significance (VUS).

127

128 **RESULTS**

129

130 We analyzed 79 individuals with TAD. The majority of patients presented a non-
131 syndromic vascular phenotype; eight were diagnosed with MFS. Seventy-two patients were
132 tested by tNGS and 7 MFS individuals were submitted to FBN1 direct sequencing screening.
133 No variants were detected in EFEMP2, FOXE3, SMAD2 and TGFB1. According to
134 ACMG/AMP guidelines for variant classification we defined 5 PV, 5 LPV, and 19 VUS (Table
135 1 and 2). Sequencing artifacts and likely benign variants were excluded.

136 The highest incidence of clinically relevant variants was found in the FBN1 gene, with
137 4 PV and 2 LPV (Figure 1), of these the majority of patients had MFS, and two presented
138 with isolated aortopathy. The others PV/LPV were found once in each of the following genes:
139 ACTA2, TGFB2R, MYLK, and SMAD3. Overall, there were 2 nonsense variants, four
140 missense variants, two frameshift deletions, and two splice site variants. Six variants have
141 been previously reported in association with MFS/TAA or cited in ClinVar database in an
142 aorta disease case. We identified four novel variants in this cohort, of which the truncation
143 variant p.Glu2019Ter in FBN1 was recently reported by our group in association with MFS
144 (18). Hereafter, we detail each variant and the ACMG criteria used for pathogenicity
145 classification.

146

147 **FBN1**

148 The missense variants in the FBN1 gene, p.Gly560Val and p.Arg1530Cys, were
149 classified as pathogenic and likely pathogenic, respectively. The FBN1 gene is intolerant to
150 missense variants as demonstrated by the gnomAD Z score value (5.06). Regarding
151 missense variants are a common mechanism of pathogenicity for MFS and TAD (19,20), we
152 applied the PP2 criterion to both variants. REVEL (Rare Variant Ensemble Learner) score
153 was used for in-silico effect prediction of rare missense variants according to Pejaver et al.

154 (16). The variants p.Gly560Val and p.Arg1530Cys scored 0.945 and 0.871, which fit the
155 PP3_strong and PP3_moderate criteria, respectively. Detection of the p.Gly560Val confirmed
156 the clinical diagnosis of SMF of patient AO94. The p.Arg1530Cys variant have been linked to
157 MFS as well as TAD in various publications (21-29), however, the patient AO56, who carries
158 it, experienced an aortic dissection at the age of 38y without an associated syndromic
159 phenotype.

160 The nonsense variant p.Arg429Ter in FBN1, identified in a female individual with
161 MFS (AO45), is a known PV. Absent in the gnomAD database, the p.Arg429Ter variant has
162 been reported in several individuals with MFS and has been found to segregate with the
163 disease in families (30-34). This supports the application of PM2_supporting, PS4_Strong
164 and PP1 criteria. The premature termination codon (PTC) generated by the variant is
165 expected to lead to gene dysfunction through protein truncation or nonsense-mediated
166 mRNA decay, which fills the PVS1 criterion.

167

168 **TGFBR2**

169 The missense variant c.1454G>A (p.Arg485His) in the Transforming Growth Factor- β
170 receptor gene (TGFBR2) holds well-established clinical significance, being associated with
171 individuals with SMF, LDS, and familial thoracic aortic dissection in multiple studies (35-40).
172 Despite its high prevalence in affected individuals, the frequency of this variant in gnomAD is
173 rare, which supports the application of criteria PS4 and PM2_support, respectively.
174 Additional gnomAD data indicates that the p.Arg485His variant is located in a hotspot region
175 of the TGFBR2 gene, as all 18 VUS/PV described in ClinVar are confined to the region
176 between exon 5 and 8 (PM1). Pannu et al. (36) reported the cosegregation of this variant
177 with the phenotype of familial TAA and dissection with reduced penetrance in two unrelated
178 families (PP1). The REVEL score for the p.Arg485His variant is 0.900, in line with the
179 PP3_moderate criterion. Due to the combined evidence from criteria PS4, PM1,
180 PM2_support, PP1, and PP3_moderate, the p.Arg485His variant is classified as pathogenic.

181 The variant was detected in a male patient (AO86) diagnosed at 48y with acute aortic
182 syndrome, extracardiac affections (syndrome not diagnosed) and positive family history of
183 cardiac death.

184

185 **SMAD3**

186 This gene is part of a group of genes recently associated with HTAD (41). The variant
187 at the canonical splicing site (c.872-2A>G) in the SMAD3 gene results in loss of function of
188 the gene product, which is an established mechanism of pathogenicity in SMAD3 (PVS1)
189 (9,42). This variant is absent from gnomAD (PM2_support) and has a single submission in
190 ClinVar associated with TAA and dissection (PS4_supporting). This PV (PVS1,
191 PM2_supporting and PS4_supporting) was detected in a male patient diagnosed at the age
192 of 35y with a 5.1 cm ascending aortic aneurysm.

193

194 **ACTA2**

195 The missense variant p.Arg314Gln (c.941G>A) in the ACTA2 gene has an annotation
196 in ClinVar as a VUS in a TAA case, and is absent in population database (PM2_supporting).
197 The REVEL score of 0.939 indicates the PP3_strong criterion. The ACTA2 gene is intolerant
198 to missense mutations (missense Z score = 3.2), and this type of mutation is a pathogenic
199 mechanism in this gene, which fulfills the PP2 criterion. Due to the combination of
200 PP3_strong, PM2_supporting, and PP2 criteria, the variant has been classified as likely
201 pathogenic. The patient carrying this variant is female and has a positive family history. The
202 diagnosis of TAA occurred at 48y, with an urgent surgical recommendation.

203

204 **Novel variants:**

205

206 **FBN1**

207 The FBN1 variant c.1837+1G>C affects the canonical splicing site critical for proper
208 mRNA processing. *In silico* evidence from ASSP (Alternative Splice Site Predictor) and
209 Splice AI indicates the loss of the critical donor site, followed exon skipping and truncated
210 product formation (PVS1). The variant has not been reported in the gnomAD or ClinVar
211 databases, neither in any publication (PM2_support). On the other hand, two different
212 variants at the same locus have been associated with fibrillinopathy/SMF (c.1837+1G>T [43];
213 c.1837+1G>A [44]). Thus, this variant has been classified as pathogenic based on the
214 combination of PVS1, PM2_support, and PS1 criteria. This variant was detected in a man
215 diagnosed with ascending aortic dissection at 50y and positive family history of cardiac
216 death.

217 The deletion c.7929_7930delTG in FBN1 alters the reading frame of the mRNA,
218 resulting in a frameshift and generating a PTC, which is expected to lead to the absence of
219 the gene product through nonsense-mediated decay (NMD) (15). This variant has not yet
220 been reported in any publications or databases (PM2_support). Therefore, based on the
221 combination of PVS1 and PM2_support criteria, we classified this variant as likely
222 pathogenic. The patient that harbors this variant is a female with MFS and aortic aneurysm
223 diagnosed at 8y.

224

225 **MYLK**

226 A frameshift deletion c.4848delG in the myosin light chain kinase gene (MYLK) has
227 been classified as likely pathogenic based on the following criteria: PVS1 due to gene loss of
228 function through NMD; PM2_support due to absence in the gnomAD database. The patient
229 with this variant is male, with a negative family history. He was diagnosed at 60y with TAA,
230 requiring emergency surgery, and presenting with an ascending aorta diameter of 7.3 cm.

231

232 **Diagnosis yield**

233

234 PV/LPV were identified in five patients out of 70 individuals with non-syndromic
235 aortopathies resulting in an isolated aortopathy diagnosis rate of 7.1% through tNGS. The
236 diagnostic yield for syndromic aortopathies (8 MFS and 1 undefined syndrome) cases was
237 55.5%, identifying five patients with PV/LPV.

238

239 **Variants of Uncertain Significance**

240

241 Nineteen VUS were detected in this cohort following the classification of reportable
242 variants. Mutations of the following types were observed: missense (11), synonymous (5),
243 one frameshift deletion, and two SNV in UTR. Five variants are novel, and 14 variants have
244 already been reported in ClinVar. The majority of VUS were identified in the FBN1 (7) and
245 MYLK (3) genes, followed by PRKG1 (2), MYH11 (2), and TGF β 2 (2), with one variant in the
246 remaining genes: COL3A1, MFAP5, and LOX (Table 2).

247 Two potentially pathogenic VUS in FBN1 were identified in individuals without
248 PV/LPV. These variants did not meet the sufficient criteria for pathogenicity/benignity, due
249 the insufficient available evidences at this time to determine the role of this variation in the
250 disease. However, they stand out from other VUS by nearly reaching the required
251 combination for classification as LPV.

252 The variant p.Asp591Gly is located in the most missense-intolerant region of the
253 FBN1 gene (O/E missense: 0.41). It has a low population frequency (0.000003980) in
254 gnomAD database, with only one allele detected in the Latin/Amerindian population. We
255 consider PM2_supporting for MAF<0.002% (45). The REVEL score indicates the PP3_sup
256 criterion. The combination of criteria PM1, PP2, PM2_sup, and PP3_sup for this VUS was
257 insufficient to reach a level of pathogenicity. Patient AO42, who carries this mutation, has
258 been diagnosed with aortic dissection at 48y and has a positive family history related to
259 cardiac death.

260 The VUS p.Ile1455Ser in the FBN1 gene also had only 1 allele found in gnomAD, but
261 it has already been reported in individuals with MFS/TAD in ClinVar and in a publication (46).
262 The REVEL score was compatible with PP3_mod. The carrier patient (AO88) was primarily
263 diagnosed with ascending aortic aneurysm at the age of 58y.

264

265 **DISCUSSION**

266

267 TAD is a silent and highly morbid condition, and a prompt diagnosis and early
268 intervention can save lives (47,48). Therefore, genetic screening becomes a significant tool
269 for early identification, follow-up, and monitoring of high-risk patients, as well as for
270 determining the course of action (48). In this study, a population with a TAD diagnosis age of
271 ≤ 60 years was selected, given that this age group exhibits a lower incidence of sporadic TAD
272 (49). An average age of early clinical presentation was observed at 44.6y (± 14.3), with a

273 male predominance (63.3%) and 51.9% being of white ethnicity, consistent with observed in
274 other studies (50-52).

275 In the present study, targeted-Next Generation Sequencing (tNGS) was conducted to
276 identify mutations in genes primarily associated with TAD in 71 patients from a tertiary
277 cardiology hospital. A total of 29 reportable variants were identified, comprising 5 PV, 5 LPV,
278 and 19 VUS. Among isolated aortopathies, our diagnostic yield was 7.1%. Other studies
279 employing tNGS for the investigation of non-syndromic aortopathies reported a diagnostic
280 yield of 4.9% for PV in 1025 patients analyzed (15 sequenced genes) (48) and 16.9% for
281 PV/LPV in 32 genes analyzed (11). Despite the higher yield in the latter work in comparison
282 of our results, SMAD2 was the only additional gene with mutations detected in Thoracic
283 Aortic Aneurysm and Dissection (TAAD) (11).

284 The above studies have shown that the majority of causal variant were detected in
285 the 11 priority genes. The use of Whole Exome Sequencing (WES) in the investigation for
286 aortopathies does not significantly increase the diagnostic yield of TAD, which generally does
287 not reach 20%. Ziganshin et al. (53) performed WES on 102 TAAD patients and found
288 deleterious variants in 3.9% of cases. Meanwhile, Wolford et al. (52) reported a 10.8%
289 diagnostic yield when conducting WES in cases of aortic dissection or rupture. Yang et al.
290 (54) achieved a diagnostic yield for NS-TAD of 18.7% using an investigative strategy that
291 combined tNGS, MLPA, and WES, with WES adding only 3 individuals to the positive
292 diagnosis group.

293 Initial clinical suspicion is crucial for guiding genetic testing and achieving better
294 diagnostic yield. In this study, patients with a diagnosis or suspicion of MSF were analyzed
295 through direct sequencing of FBN1, resulting in a diagnostic yield of 50%. This yield is higher
296 than that obtained by Renner et al. (11) with a multigene panel (29.8%) and lower than the
297 83.5% achieved with the combination of targeted Next-Generation Sequencing (tNGS),
298 Multiplex Ligation-dependent Probe Amplification (MLPA), and Whole Exome Sequencing
299 (WES) (53).

300 Interpreting genetic sequencing data can be challenging due to variants exhibiting
301 inconsistent characteristics for both pathogenicity and benignity (55). A guideline for
302 interpreting genetic variants in aortopathies has not yet been established. Therefore, efforts
303 dedicated to the careful classification of variants identified in patients with TAD can provide
304 significant contributions to the interpretation and molecular diagnosis of these pathologies
305 within the context of precision medicine (56).

306 Ten PV/LPV were identified in 5 of the 15 analyzed genes (FBN1, ACTA2, TGFBR2,
307 MYLK, and SMAD3), with four of these variants being reported in association with MFS/TAD
308 for the first time in this study. FBN1 had the highest incidence, with six identified variants,
309 following a similar pattern to other studies (57-59). Mutations in FBN1 were initially
310 associated with MFS (60,61); subsequent studies revealed its association with Marfan-like
311 syndromes (45,57). More recent studies have shown FBN1 variants related to NS-TAD,
312 suggesting a common pathogenesis between NS-TAD and MFS (52,59,62). Cysteine

313 substitutions in the calcium-binding of epidermal growth factor (EGF) like domains represent
314 the majority of pathogenic missense changes associated with MFS (63). However, loss of
315 function (LoF) variants were the principal type of variants discovered in our MFS cohort,
316 followed by a glycine to valine substitution in the EGF-like 8 domain. One missense and one
317 LoF variant were detected in non-syndromic aortopathies. Haploinsufficiency of fibrillin-1 is a
318 pathogenic mechanism for both MFS (64,65) and NS-TAD (54). Missense mutations can also
319 lead to decreased fibrillin secretion due to improper protein folding (66). In these cases,
320 missense mutations and frameshift LoF mutations would share the haploinsufficiency
321 mechanism.

322 FBN1 was also prevalent in VUS (7). Of all VUS, only one (FBN1-p.Ile849Met) was
323 found in an individual carrying a PV. On the other hand, two missense VUS identified in
324 individuals with isolated aortopathies have the potential to be upgraded to LPV or PV. One of
325 them (FBN1-p.Asp591Gly) is being reported for the first time in this study. The second VUS
326 has previously been reported as an LPV for MFS (46); however, there is still a lack of
327 evidence in the literature to define its burden. Reporting our findings will contribute to
328 potentially elevating a VUS to a causal variant in the future. Investigating families could
329 provide information lacking for the definitive association of VUS with the disease;
330 unfortunately, we did not have access to the families in this study.

331 In this study, PV/LPV were also found in the genes ACTA2, TGFBR2, MYLK, and
332 SMAD3, for which gene-disease validity is definitive or strong for familial TAAD. Mutations in
333 smooth muscle cell-specific genes (ACTA2, MYLK, MYH11) have been discovered in
334 connection with familial TAAD. This characteristic typically exhibits autosomal dominant
335 inheritance within families, with varying degrees of penetrance and expressivity (67). Actin
336 alpha 2 is a highly conserved protein, and missense variants account for the majority of
337 PV/LPV in this gene. The p.Arg314Gln variant is located in exon 7, the only one where no
338 PV/LPV was annotated.

339 We identified a novel frameshift variant (c.4848delG) in MYLK with the potential to
340 disrupt protein function and result in loss of allele function through NMD. However, at this
341 time, there is limited evidence to support the haploinsufficiency of this gene, given the limited
342 number of TAAD-associated mutations in MYLK in the literature.

343 Mutations in the TGFBR2 gene have previously been associated with LDS and TAAD
344 in individuals with Marfanoid features (68,69). Patient AO86 exhibited syndromic features
345 reported as EDS type, but without a conclusive diagnosis. The identified variant has a well-
346 established association with TAD, with most studies reporting its association with isolated
347 aortopathy. However, Law et al. (37) described carriers of the Arg485His variant with
348 features overlapping EDS type 4 (OMIM 130050), such as soft translucent skin, arthralgia,
349 and varicose veins, which could be considered a distinct syndrome.

350 This investigation provides a comprehensive insight into aortopathies within a
351 Brazilian cohort, highlighting the genetic diversity inherent in these conditions. The
352 implementation of tNGS yielded a notable diagnostic rate, uncovering PV/LPV in genes

353 associated with aortic diseases. The prevalence of mutations in the FBN1 gene, particularly
354 among patients with both syndromic and non-syndromic Marfan-like features, underscores its
355 clinical significance and underscores the necessity for an individualized approach in
356 managing these cases. Furthermore, the identification of novel variants, whether associated
357 with known syndromic phenotypes or not, contributes to the growing understanding of the
358 genetic complexity of aortopathies. These findings underscore the importance of precise
359 genetic screening as a fundamental tool for early intervention and personalized therapeutic
360 strategies, paving the way for significant advancements toward precision medicine in the
361 context of aortopathies.

362

363 **Acknowledgments**

364 The authors would like to thank the patients enrolled in this study and the support of INC and
365 FAPERJ.

366

367 **Author contributions**

368 **JRF** - Conduction of the work, patient selection and recruitment, clinical evaluation, data
369 collection and analysis, variant analysis, manuscript writing.

370 **JPP** – Samples processing and NGS.

371 **APAB** - Samples processing and Sanger sequencing.

372 **DNA** - Analysis of NGS data and variants interpretation.

373 **MMM** – Patients selection and recruitment, supervision of clinical evaluation.

374 **HCVR** – Data analysis, study supervision.

375 **GMD** – Study idealization, variant analysis, manuscript writing.

376

377 **Declaration of interests**

378

379 The authors declare no competing interests.

380

381 **REFERENCES**

382

- 383 1. Faggion Vinholo T, Brownstein AJ, Ziganshin BA, Zafar MA, Kuivaniemi H, Body SC, et
384 al. Genes Associated with Thoracic Aortic Aneurysm and Dissection: 2019 Update and
385 Clinical Implications. *Aorta (Stamford)*. 2019;07(04):099-107.
- 386 2. Sellke FW, Sellke FW, Coselli JS, Sundt TM, SpringerLink. Aortic dissection and acute
387 aortic syndromes. 1st 2021. ed. Cham, Switzerland: Springer Nature Switzerland AG,
388 2021. 1 online resource (viii, 659 pages): illustrations p.
- 389 3. Centers for Disease Control and Prevention (CDC). Data and stats, aortic aneurysms.
390 About Multiple Cause of Death, 1999–2019. CDC WONDER Online Database website;
391 2021. https://www.cdc.gov/heartdisease/aortic_aneurysm.htm, Accessed October 19,
392 2023.

- 393 4. MS/SVS/CGIAE - Sistema de Informações sobre Mortalidade - SIM. Óbitos p/Residênc
394 segundo Região 2020 [Available from:
395 <http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sim/cnv/obt10uf.def>.
- 396 5. Oladokun D, Patterson BO, Sobocinski J, Karthikesalingam A, Loftus I, Thompson MM,
397 et al. Systematic Review of the Growth Rates and Influencing Factors in Thoracic Aortic
398 Aneurysms. *Eur J Vasc Endovasc Surg*. 2016;51(5):674-81.
- 399 6. Guo, D. C. Regalado, E. S., Minn, C., Tran-Fadulu, V., Coney, J., Cao, J., Wang, M., Yu,
400 R. K., Estrera, A.L., Safi, H. J., Shete, S. S., & Milewicz, D. M. (2011). Familial Thoracic
401 Aortic Aneurysms and Dissections. *Circulation: Cardiovascular Genetics*, 4(1), 36–42.
- 402 7. Fletcher AJ, Syed MJB, Aitman TJ, Newby DE, Walker NL. Inherited Thoracic Aortic
403 Disease: New Insights and Translational Targets. *Circulation*. 2020 May
404 12;141(19):1570-1587.
- 405 8. Ahmad MM, Kiani IA, Ammar KA, Ahmad MN, Khandheria BK, Paterick TE, et al.
406 Ascending Aortic Aneurysm Is an Inherited Disease: A Contemporary Literature Review
407 Based on Hill's Criteria of Specificity, Strength of Association, and Biological Coherence.
408 *Cardiol Rev*. 2017;25(6):268-78.
- 409 9. Regalado ES, Guo DC, Villamizar C, Avidan N, Gilchrist D, McGillivray B, et al. Exome
410 sequencing identifies SMAD3 mutations as a cause of familial thoracic aortic aneurysm
411 and dissection with intracranial and other arterial aneurysms. *Circ Res*. 2011;109(6):680-
412 6.
- 413 10. Pinard A, Jones GT, Milewicz DM. Genetics of Thoracic and Abdominal Aortic Diseases.
414 *Circ Res*. 2019;124(4):588-606.
- 415 11. Renner S, Schüler H, Alawi M, Kolbe V, Rybczynski M, Woitschach R, Sheikhzadeh S,
416 Stark VC, Olfe J, Roser E, Seggewies FS, Mahlmann A, Hempel M, Hartmann MJ,
417 Hillebrand M, Wieczorek D, Volk AE, Kloth K, Koch-Hogrebe M, Abou Jamra R, Mitter D,
418 Altmüller J, Wey-Fabrizius A, Petersen C, Rau I, Borck G, Kubisch C, Mir TS, von
419 Kodolitsch Y, Kutsche K, Rosenberger G. Next-generation sequencing of 32 genes
420 associated with hereditary aortopathies and related disorders of connective tissue in a
421 cohort of 199 patients. *Genet Med*. 2019 Aug;21(8):1832-1841.
- 422 12. Verstraeten A, Alaerts M, Van Laer L, Loeys B. Marfan syndrome and related disorders:
423 25 years of gene discovery. *Hum Mutat*. 2016;37(6):524-31.
- 424 13. Renard M, Francis C, Ghosh R, Scott AF, Witmer PD, Adès LC, et al. Clinical Validity of
425 Genes for Heritable Thoracic Aortic Aneurysm and Dissection. *J Am Coll Cardiol*.
426 2018;72(6):605-15.
- 427 14. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and
428 guidelines for the interpretation of sequence variants: a joint consensus recommendation
429 of the American College of Medical Genetics and Genomics and the Association for
430 Molecular Pathology. *Genet Med*. 2015;17(5):405-24.
- 431 15. Abou Tayoun et al., Pesaran T, DiStefano MT, Oza A, Rehm HL, Biesecker LG, Harrison
432 SM; ClinGen Sequence Variant Interpretation Working Group (ClinGen SVI).

- 433 Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant
434 criterion. *Hum Mutat.* 2018 Nov;39(11):1517-1524.
- 435 16. Pejaver V, Byrne AB, Feng BJ, Pagel KA, Mooney SD, Karchin R, O'Donnell-Luria A,
436 Harrison SM, Tavtigian SV, Greenblatt MS, Biesecker LG, Radivojac P, Brenner SE;
437 ClinGen Sequence Variant Interpretation Working Group. Calibration of computational
438 tools for missense variant pathogenicity classification and ClinGen recommendations for
439 PP3/BP4 criterion. *Am J Hum Genet.* 2022 Dec 1;109(12):2163-2177.
- 440 17. Walker LC, de la Hoya M, Wiggins GAR, Lindy A, Vincent LM, Parsons MT, Canson DM,
441 Bis-Brewer D, Cass A, Tchourbanov A, Zimmermann H, Byrne AB, Pesaran T, Karam R,
442 Harrison S, Spurdle AB. Application of the ACMG/AMP framework to capture evidence
443 relevant to predicted and observed impact on splicing: recommendations from the
444 ClinGen SVI Splicing subgroup. *medRxiv [Preprint]*. 2023 Feb 26:2023.02.24.23286431.
445 Update in: *Am J Hum Genet.* 2023 Jun
- 446 18. Pereira JP, Ferreira JR, Botelho APA, Melo MM, Dias GM. Identification of a novel
447 pathogenic variant in FBN1 associated with Marfan Syndrome. *Cold Spring Harb Mol*
448 *Case Stud.* 2022 May 19;8(4):a006215.
- 449 19. Ghosh R, Oak N, Plon SE. Evaluation of in silico algorithms for use with ACMG/AMP
450 clinical variant interpretation guidelines. *Genome Biol.* 2017 Nov 28;18(1):225.
- 451 20. Sakai LY, Keene DR, Renard M, De Backer J. FBN1: The disease-causing gene for
452 Marfan syndrome and other genetic disorders. *Gene.* 2016 Oct 10;591(1):279-291.
- 453 21. Jin C, Yao K, Jiang J, Tang X, Shentu X, Wu R. Novel FBN1 mutations associated with
454 predominant ectopia lentis and marfanoid habitus in Chinese patients. *Mol Vis.* 2007 Jul
455 24; 13:1280-4.
- 456 22. Aragon-Martin JA, Ahnood D, Charteris DG, Saggar A, Nischal KK, Comeglio P,
457 Chandra A, Child AH, Arno G. Role of ADAMTSL4 mutations in FBN1 mutation-negative
458 ectopia lentis patients. *Hum Mutat.* 2010 Aug;31(8):E1622-31.
- 459 23. Biggin A, Holman K, Brett M, Bennetts B, Adès L. Detection of thirty novel FBN1
460 mutations in patients with Marfan syndrome or a related fibrillinopathy. *Hum Mutat.* 2004
461 Jan;23(1):99.
- 462 24. Howarth R, Yearwood C, Harvey JF. Application of dHPLC for mutation detection of the
463 fibrillin-1 gene for the diagnosis of Marfan syndrome in a National Health Service
464 Laboratory. *Genet Test.* 2007 Summer;11(2):146-52.
- 465 25. Loeys B, Nuytinck L, Delvaux I, De Bie S, De Paepe A. Genotype and phenotype
466 analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because
467 of suspected Marfan syndrome. *Arch Intern Med.* 2001 Nov 12;161(20):2447-54.
- 468 26. Rand-Hendriksen S, Tjeldhorn L, Lundby R, Semb SO, Offstad J, Andersen K, Geiran O,
469 Paus B. Search for correlations between FBN1 genotype and complete Ghent
470 phenotype in 44 unrelated Norwegian patients with Marfan syndrome. *Am J Med Genet*
471 *A.* 2007 Sep 1;143A(17):1968-77.

- 472 27. Villamizar C, Regalado ES, Fadulu VT, Hasham SN, Gupta P, Willing MC, Kuang SQ,
473 Guo D, Muilenburg A, Yee RW, Fan Y, Towbin J, Coselli JS, LeMaire SA, Milewicz DM.
474 Paucity of skeletal manifestations in Hispanic families with FBN1 mutations. *Eur J Med*
475 *Genet.* 2010 Mar-Apr;53(2):80-4.
- 476 28. Wang WJ, Han P, Zheng J, Hu FY, Zhu Y, Xie JS, Guo J, Zhang Z, Dong J, Zheng GY,
477 Cao H, Liu TS, Fu Q, Sun L, Yang BB, Tian XL. Exon 47 skipping of fibrillin-1 leads
478 preferentially to cardiovascular defects in patients with thoracic aortic aneurysms and
479 dissections. *J Mol Med (Berl)*. 2013 Jan;91(1):37-47.
- 480 29. Yoo EH, Woo H, Ki CS, Lee HJ, Kim DK, Kang IS, Park P, Sung K, Lee CS, Chung TY,
481 Moon JR, Han H, Lee ST, Kim JW. Clinical and genetic analysis of Korean patients with
482 Marfan syndrome: possible ethnic differences in clinical manifestation. *Clin Genet.* 2010
483 Feb;77(2):177-82.
- 484 30. Rommel K, Karck M, Haverich A, Schmidtke J, Arslan-Kirchner M. Mutation screening of
485 the fibrillin-1 (FBN1) gene in 76 unrelated patients with Marfan syndrome or Marfanoid
486 features leads to the identification of 11 novel and three previously reported mutations.
487 *Hum Mutat.* 2002 Nov;20(5):406-7.
- 488 31. Sakai H, Visser R, Ikegawa S, Ito E, Numabe H, Watanabe Y, Mikami H, Kondoh T,
489 Kitoh H, Sugiyama R, Okamoto N, Ogata T, Fodde R, Mizuno S, Takamura K, Egashira
490 M, Sasaki N, Watanabe S, Nishimaki S, Takada F, Nagai T, Okada Y, Aoka Y, Yasuda
491 K, Iwasa M, Kogaki S, Harada N, Mizuguchi T, Matsumoto N. Comprehensive genetic
492 analysis of relevant four genes in 49 patients with Marfan syndrome or Marfan-related
493 phenotypes. *Am J Med Genet A.* 2006 Aug 15;140(16):1719-25.
- 494 32. Attanasio M, Lapini I, Evangelisti L, Lucarini L, Giusti B, Porciani M, Fattori R, Anichini C,
495 Abbate R, Gensini G, Pepe G. FBN1 mutation screening of patients with Marfan
496 syndrome and related disorders: detection of 46 novel FBN1 mutations. *Clin Genet.*
497 2008 Jul;74(1):39-46.
- 498 33. Magyar I, Colman D, Arnold E, Baumgartner D, Bottani A, Fokstuen S, Addor MC,
499 Berger W, Carrel T, Steinmann B, Mátyás G. Quantitative sequence analysis of FBN1
500 premature termination codons provides evidence for incomplete NMD in leukocytes.
501 *Hum Mutat.* 2009 Sep;30(9):1355-64.
- 502 34. Yang H, Luo M, Chen Q, Fu Y, Zhang J, Qian X, Sun X, Fan Y, Zhou Z, Chang Q.
503 Genetic testing of the FBN1 gene in Chinese patients with Marfan/Marfan-like syndrome.
504 *Clin Chim Acta.* 2016 Aug 1;459:30-35.
- 505 35. Disabella E, Grasso M, Marziliano N, Ansaldi S, Lucchelli C, Porcu E, Tagliani M, Pilotto
506 A, Diegoli M, Lanzarini L, Malattia C, Pelliccia A, Ficcadenti A, Gabrielli O, Arbustini E.
507 Two novel and one known mutation of the TGFBR2 gene in Marfan syndrome not
508 associated with FBN1 gene defects. *Eur J Hum Genet.* 2006 Jan;14(1):34-8.
- 509 36. Pannu H, Fadulu VT, Chang J, Lafont A, Hasham SN, Sparks E, Giampietro PF, Zaleski
510 C, Estrera AL, Safi HJ, Shete S, Willing MC, Raman CS, Milewicz DM. Mutations in

- 511 transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms
512 and dissections. *Circulation*. 2005 Jul 26;112(4):513-20.
- 513 37. Law C, Bunyan D, Castle B, Day L, Simpson I, Westwood G, Keeton B. Clinical features
514 in a family with an R460H mutation in transforming growth factor beta receptor 2 gene. *J*
515 *Med Genet*. 2006 Dec;43(12):908-16.
- 516 38. Campens L, Callewaert B, Muiño Mosquera L, Renard M, Symoens S, De Paepe A,
517 Coucke P, De Backer J. Gene panel sequencing in heritable thoracic aortic disorders
518 and related entities - results of comprehensive testing in a cohort of 264 patients.
519 *Orphanet J Rare Dis*. 2015 Feb 3;10:9.
- 520 39. Singh KK, Rommel K, Mishra A, Karck M, Haverich A, Schmidtke J, Arslan-Kirchner M.
521 TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and
522 Loeys-Dietz syndrome. *Hum Mutat*. 2006 Aug;27(8):770-7.
- 523 40. Guerrerio AL, Frischmeyer-Guerrerio PA, Huang C, Wu Y, Haritunians T, McGovern
524 DPB, MacCarrick GL, Brant SR, Dietz HC. Increased Prevalence of Inflammatory Bowel
525 Disease in Patients with Mutations in Genes Encoding the Receptor Subunits for TGFβ.
526 *Inflamm Bowel Dis*. 2016 Sep;22(9):2058-2062.
- 527 41. Takeda N, Komuro I. Genetic basis of hereditary thoracic aortic aneurysms and
528 dissections. *J Cardiol*. 2019 Aug;74(2):136-143.
- 529 42. Aubart M, Gobert D, Aubart-Cohen F, Detaint D, Hanna N, d'Indya H, Lequintrec JS,
530 Renard P, Vigneron AM, Dieudé P, Laissy JP, Koch P, Muti C, Roume J, Cusin V,
531 Grandchamp B, Gouya L, LeGuern E, Papo T, Boileau C, Jondeau G. Early-onset
532 osteoarthritis, Charcot-Marie-Tooth like neuropathy, autoimmune features, multiple
533 arterial aneurysms and dissections: an unrecognized and life threatening condition.
534 *PLoS One*. 2014 May 7;9(5):e96387.
- 535 43. Stheneur C, Collod-Bérout G, Faivre L, Buyck JF, Gouya L, Le Parc JM, Moura B, Muti
536 C, Grandchamp B, Sultan G, Claustres M, Aegerter P, Chevallier B, Jondeau G, Boileau
537 C. Identification of the minimal combination of clinical features in probands for efficient
538 mutation detection in the FBN1 gene. *Eur J Hum Genet*. 2009 Sep;17(9):1121-8.
- 539 44. Loeys B, De Backer J, Van Acker P, Wettinck K, Pals G, Nuytinck L, Coucke P, De
540 Paepe A. Comprehensive molecular screening of the FBN1 gene favors locus
541 homogeneity of classical Marfan syndrome. *Hum Mutat*. 2004 Aug;24(2):140-6.
- 542 45. Harrison SM, Biesecker LG, Rehm HL. Overview of Specifications to the ACMG/AMP
543 Variant Interpretation Guidelines. *Curr Protoc Hum Genet*. 2019 Sep;103(1):e93.
- 544 46. Lerner-Ellis JP, Aldubayan SH, Hernandez AL, Kelly MA, Stuenkel AJ, Walsh J, Joshi
545 VA. The spectrum of FBN1, TGFβR1, TGFβR2 and ACTA2 variants in 594 individuals
546 with suspected Marfan Syndrome, Loeys-Dietz Syndrome or Thoracic Aortic Aneurysms
547 and Dissections (TAAD). *Mol Genet Metab*. 2014 Jun;112(2):171-6.
- 548 47. Johansson G, Markstrom U, Swedenborg J. Ruptured thoracic aortic aneurysms: a study
549 of incidence and mortality rates. *J Vasc Surg*. 1995;21(6):985-8.

- 550 48. Weerakkody R, Ross D, Parry DA, Ziganshin B, Vandrovцова J, Gampawar P, Abdullah
551 A, Biggs J, Dumfarth J, Ibrahim Y; Yale Aortic Institute Data and Repository Team;
552 Bicknell C, Field M, Elefteriades J, Cheshire N, Aitman TJ. Targeted genetic analysis in
553 a large cohort of familial and sporadic cases of aneurysm or dissection of the thoracic
554 aorta. *Genet Med*. 2018 Nov;20(11):1414-1422.
- 555 49. Isselbacher EM, Preventza O, Hamilton Black J 3rd, Augoustides JG, Beck AW, Bolen
556 MA, Braverman AC, Bray BE, Brown-Zimmerman MM, Chen EP, Collins TJ, DeAnda A
557 Jr, Fanola CL, Girardi LN, Hicks CW, Hui DS, Schuyler Jones W, Kalahasti V, Kim KM,
558 Milewicz DM, Oderich GS, Ogbechie L, Promes SB, Gyang Ross E, Schermerhorn ML,
559 Singleton Times S, Tseng EE, Wang GJ, Woo YJ. 2022 ACC/AHA Guideline for the
560 Diagnosis and Management of Aortic Disease: A Report of the American Heart
561 Association/American College of Cardiology Joint Committee on Clinical Practice
562 Guidelines. *Circulation*. 2022 Dec 13;146(24):e334-e482.
- 563 50. Trimarchi S, Nienaber CA, Rampoldi V, Myrmet T, Suzuki T, Mehta RH, et al.
564 Contemporary results of surgery in acute type A aortic dissection: The International
565 Registry of Acute Aortic Dissection experience. *J Thorac Cardiovasc Surg*.
566 2005;129(1):112-22.
- 567 51. Sherrah AG, Andvik S, van der Linde D, Davies L, Bannon PG, Padang R, et al.
568 Nonsyndromic Thoracic Aortic Aneurysm and Dissection: Outcomes With Marfan
569 Syndrome Versus Bicuspid Aortic Valve Aneurysm. *J Am Coll Cardiol*. 2016;67(6):618-
570 26.
- 571 52. Wolford BN, Hornsby WE, Guo D, Zhou W, Lin M, Farhat L, et al. Clinical Implications of
572 Identifying Pathogenic Variants in Individuals With Thoracic Aortic Dissection. *Circ*
573 *Genom Precis Med*. 2019;12(6):e002476.
- 574 53. Ziganshin BA, Bailey AE, Coons C, Dykas D, Charilaou P, Tanriverdi LH, et al. Routine
575 Genetic Testing for Thoracic Aortic Aneurysm and Dissection in a Clinical Setting. *Ann*
576 *Thorac Surg*. 2015;100(5):1604-11.
- 577 54. Yang H, Shen H, Zhu G, Shao X, Chen Q, Yang F, Zhang Y, Zhang Y, Zhao K, Luo M,
578 Zhou Z, Shu C. Molecular characterization and clinical investigation of patients with
579 heritable thoracic aortic aneurysm and dissection. *J Thorac Cardiovasc Surg*. 2022 Nov
580 12:S0022-5223(22)01234-X.
- 581 55. Koboldt, D.C. Best practices for variant calling in clinical sequencing. *Genome Med* 12,
582 91 (2020).
- 583 56. Ponińska JK, Bilińska ZT, Truszkowska G, Michalak E, Podgórska A, Stępień-Wojno M,
584 Chmielewski P, Lutyńska A, Płoski R. Good performance of the criteria of American
585 College of Medical Genetics and Genomics/Association for Molecular Pathology in
586 prediction of pathogenicity of genetic variants causing thoracic aortic aneurysms and
587 dissections. *J Transl Med*. 2022 Jan 25;20(1):42.

- 588 57. Wooderchak-Donahue W, VanSant-Webb C, Tvrđik T, Plant P, Lewis T, Stocks J, et al.
589 Clinical utility of a next generation sequencing panel assay for Marfan and Marfan-like
590 syndromes featuring aortopathy. *Am J Med Genet A*. 2015;167A(8):1747-57.
- 591 58. Poninska JK, Bilinska ZT, Franaszczyk M, Michalak E, Rydzanicz M, Szpakowski E, et
592 al. Next-generation sequencing for diagnosis of thoracic aortic aneurysms and
593 dissections: diagnostic yield, novel mutations and genotype phenotype correlations. *J*
594 *Transl Med*. 2016;14(1):115.
- 595 59. Proost D, Vandeweyer G, Meester JA, Salemink S, Kempers M, Ingram C, et al.
596 Performant mutation identification using targeted next-generation sequencing of 14
597 thoracic aortic aneurysm genes. *Hum Mutat*. 2015;36(8):808-14.
- 598 60. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, et al. Marfan
599 syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. *Nature*.
600 1991;352(6333):337-9.
- 601 61. Maslen CL, Corson GM, Maddox BK, Glanville RW, Sakai LY. Partial sequence of a
602 candidate gene for the Marfan syndrome. *Nature*. 1991;352(6333):334-7.
- 603 62. Fang M, Yu C, Chen S, Xiong W, Li X, Zeng R, et al. Identification of Novel Clinically
604 Relevant Variants in 70 Southern Chinese patients with Thoracic Aortic Aneurysm and
605 Dissection by Next-generation Sequencing. *Sci Rep*. 2017;7(1):10035.
- 606 63. Collod-Bérout G, Le Bourdelles S, Ades L, Ala-Kokko L, Booms P, Boxer M, Child A,
607 Comeglio P, De Paepe A, Hyland JC, Holman K, Kaitila I, Loeys B, Mátyás G, Nuytinck
608 L, Peltonen L, Rantamaki T, Robinson P, Steinmann B, Junien C, Bérout C, Boileau C.
609 Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism
610 database. *Hum Mutat*. 2003 Sep;22(3):199-208.
- 611 64. Mátyás G, Alonso S, Patrignani A, Marti M, Arnold E, Magyar I, Henggeler C, Carrel T,
612 Steinmann B, Berger W. Large genomic fibrillin-1 (FBN1) gene deletions provide
613 evidence for true haploinsufficiency in Marfan syndrome. *Hum Genet*. 2007
614 Aug;122(1):23-32.
- 615 65. Li J, Wu W, Lu C, Liu Y, Wang R, Si N, Liu F, Zhou J, Zhang S, Zhang X. Gross
616 deletions in FBN1 results in variable phenotypes of Marfan syndrome. *Clin Chim Acta*.
617 2017 Nov;474:54-59.
- 618 66. Whiteman P, Hutchinson S, Handford PA. Fibrillin-1 misfolding and disease. *Antioxid*
619 *Redox Signal*. 2006;8:338–346.
- 620 67. Albornoz G, Coady MA, Roberts M, Davies RR, Tranquilli M, Rizzo JA, Elefteriades JA.
621 Familial thoracic aortic aneurysms and dissections--incidence, modes of inheritance, and
622 phenotypic patterns. *Ann Thorac Surg*. 2006 Oct;82(4):1400-5.
- 623 68. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular,
624 craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1
625 or TGFBR2. *Nat Genet*. 2005;37:275–281.

- 626 69. Mizuguchi T, Collod-Beroud G, Akiyama T, et al. Heterozygous TGFBR2 mutations in
627 Marfan syndrome. *Nat Genet.* 2004;36:855–860.

628 **FIGURE LEGEND**

629

630

631 **Figure 1** – Structure of the FBN1 gene representing the respective domains of the fibrillin-1
632 protein. The six VP/VPP identified in the FBN1 gene are pointed. EGF: epidermal growth
633 factor-like domains; cb-EGF: EGF-like domains with a calcium-binding domain; TB domain:
634 domains similar to TGF- β binding proteins; hybrid: hybrid containing characteristics of the TB
635 and cb-EGF domains

636

637 **TABLES**

Table 1. Pathogenic and likely pathogenic variants

ID	Phenotype	Gene	Locus	Transcript	Genotype	Type	Protein impact	Exon	MAF	ACMG Criteria
AO45 ^a	MFS	FBN1	chr15:48808422	NM_000138.5	c.1285C>T	Nonsense	p.Arg429Ter	11	NR	Pathogenic PVS1, PS4_str ^b , PM2_sup, PP1 ^c , PP4
AO56	Ao dissection	FBN1	chr15:48760294	NM_000138.5	c.4588C>T	Missense	p.Arg1530Cys	38	NR	Likely Pathogenic PS4_mod ^d , PM2_sup, PP1, PP2, PP3_mod
AO71 ^a	MFS	FBN1	chr15:48734026	NM_000138.5	c.6055G>T	Nonsense	p.Glu2019Ter	50	NR	Pathogenic PVS1, PM2_sup, PM6 ^e , PP1, PP4
AO84	Ao dissection	FBN1	chr15:48800778	NM_000138.5	c.1837+1G>C	Sítio de splice	p.?	15	NR	Pathogenic PVS1_str, PS1 ^f , PM2_sup
AO85	Ao dissection	ACTA2	chr10:90697867	NM_001613.4	c.941G>A	Missense	p.Arg314Gln	8	NR	Likely Pathogenic PP3_str, PM2_sup, PP2
AO86	Ao dissection/EC	TGFBR2	chr3:30715721	NM_001024847.2	c.1454G>A	Missense	p.Arg485His	6	0.000004	Pathogenic PS4 ^g , PM2_sup, PM5, PP3_mod, PP1_str ^h
AO87 ^a	MFS	FBN1	chr15:48707855	NM_000138.5	c.7929_7930delTG	Del-Frameshift	p.Ser2643ArgfsTer8	64	NR	Likely Pathogenic PVS1, PM2_sup
AO92	Ao dissection	MYLK	chr3:123357030	NM_053025.4	c.4848delG	Del-Frameshift	p.Ser1617LeufsTer2	29	NR	Likely Pathogenic PVS1, PM2_sup
AO94 ^a	MFS	FBN1	chr15:48802276	NM_000138.5	c.1679G>T	Missense	p.Gly560Val	14	NR	Pathogenic PS4_sup ⁱ , PM1, PM2_sup, PP2, PP3_str, PP4
AO99	Ao aneurysm	SMAD3	chr15:67477063	NM_005902.4	c.872-2A>G	Sítio de splice	p.?	7	NR	Likely Pathogenic PVS1_str, PS4_sup ^j , PM2_sup

ACMG, American College of Medical Genetic and Genomic; ID, subject identification; MAF, minor allele frequency in gnomAD; NR, not reported; EC, extracardiac affections; str, strong; mod, moderate; sup, supporting

^aFBN1 direct sequencing approach

^bVariante reported in several people with MFS (PMID: 12402346, 18435798, 16835936, 27234404, 19618372)

^cVariante reported cosegregation with disease in affected family members (PMID: 12402346, 16835936, 18435798)

^dVariante associated with SMF in 5 non-related people (PMID: 14695540, 17627385, 17663468, 11700157)

^eParents are not variant carriers without paternity confirmation

^fPathogenic variants with another nucleotide exchange at the same splice site +-1,2 (c.1837+1G>A/T, PMID: 19293843, 15241795)

^gVariante reported in several people with aortopathies (PMID: 16027248, 16885183, 25644172, 27508510, 23884466, 18852674)

^hVariante segregates with aortopathies in some families (PMID: 16027248, 16885183)

ⁱVariant reported in 2 MFS individuals in ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/variation/803096/>)


^jVariant reported in 1 MFS individuals in ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/variation/1968962/>)

Table 2. Variants of uncertain significance

ID	Phenotype	Gene	Locus	Transcript	Genotype	Protein impact	Exon	dbSNP	MAF	ACMG Criteria
AO12	Ao aneurysm	PRKG1	chr10:53814273	NM_006258.4	c.792C>T	p.Ile264=	6	rs1165873275	0.000003983	PM2_sup, BP4
AO32	Ao aneurysm	TGFB2	chr1:218519941	NM_001135599.3	c.-97delA	p.?	1	NR	NR	PM2_sup
AO37	Ao dissection	FBN1	chr15:48703095	NM_000138.5	c.*92T>C	p.?	66	rs1038325459	NR	PM2_sup
AO40	Ao aneurysm	MYH11	chr16:15815483	NM_001040114.1	c.4395C>G	p.Ala1465=	33	NR	NR	PM2_sup, BP4, BP7
AO42	Ao dissection	FBN1	chr15:48800844	NM_000138.5	c.1772A>G	p.Asp591Gly	15	rs1380921125	0.000003980	PM1, PM2_sup, PP2, PP3_sup
AO44	Ao aneurysm	MYLK	chr3:123471182	NM_053025.4	c.369A>T	p.Val123=	5	rs746517311	0.000003982	PM2_sup, BP7
AO45 ^a	Ao dissection	FBN1	chr15:48787450	NM_000138.5	c.2547C>G	p.Ile849Met	22	rs778258207	0.00003581	PP2, PP4, BP4_mod
AO48	Ao dissection	FBN1	chr15:48808442	NM_000138.5	c.1265G>A	p.Gly422Glu	11	rs139968089	0.00008139	PP2
AO55	Ao dissection	MYH11	chr16:15810999	NM_001040114.1	c.5523C>T	p.Ala1841=	39	NR	NR	PM2_sup, BP4, BP7
AO58	Ao dissection	COL3A1	chr2:189856420	NM_000090.4	c.923G>A	p.Arg308Gln	13	rs753589858	0.00001592	PM2_sup, PP2
AO60	Ao aneurysm	MYLK	chr3:123348391	NM_053025.4	c.5044G>A	p.Asp1682Asn	30	rs140456660	0.00001591	PM1, PM2_sup
AO69	Ao aneurysm	MFAP5	chr12:8800764	NM_003480.4	c.444delT	p.Arg149GlyfsTer28	10	rs756582294	0.00002388	PVS1_sup
AO72	Ao aneurysm	PRKG1	chr10:53814271	NM_006258.4	c.790A>G	p.Ile264Val	6	rs56082459	0.00009559	BS1
AO83	Ao dissection	FBN1	chr15:48714264	NM_000138.5	c.7455T>G	p.Asp2485Glu	61	rs377272529	0.00004603	PM5, PP3_sup
AO88	Ao aneurysm	FBN1	chr15:48762926	NM_000138.5	c.4364T>G	p.Ile1455Ser	36	rs397515807	0.000003980	PP3_mod, PS4_sup, PM2_sup, PP2
		LOX	chr5:121412658	NM_002317.7	c.670G>C	p.Ala224Pro	2	rs1282574280	NR	PM2_sup
AO95	Ao dissection	MYLK	chr3:123427680	NM_053025.4	c.2005T>G	p.Phe669Val	15	rs755957947	0.00004596	none
AO96	Ao aneurysm	FBN1	chr15:48725102	NM_000138.5	c.6700G>A	p.Val2234Met	55	rs112084407	0.0007400	PP2, BS1, BP4_sup
AO99	Ao aneurysm	TGFB2	chr1:218607783	NM_001135599.3	c.831A>G	p.Arg277=	5	rs147960792	0.00009245	none

ACMG, American College of Medical Genetic and Genomic; ID, subject identification; MAF, minor allele frequency in gnomAD; NR, not reported; EC, extracardiac affections; str, strong; mod, moderate; sup, supporting

^aFBN1 direct sequencing approach



EGF cb-EGF hybrid TB domain